Biodelivery Sciences International Patent-Cliff Exposure & CMS Drug Spending Portfolio

Biodelivery Sciences International (US): 2 reconciled FDA prescription therapies, $214.5M 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$214.5M
2024 Medicare Part D Spend$169.9M
2024 Medicaid Spend$44.6M
California HCAI SB 17 Filings24 WAC filings (max 17.4% 2-yr change)